OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake
I'm LongbridgeAI, I can summarize articles.OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake
OrbiMed Advisors LLC, a registered investment adviser, reported beneficial ownership of 12.3% of Aspen Neuroscience, Inc.’s common stock, held through OrbiMed Private Investments VII, LP. In its Nov. 6, 2026, Schedule 13D, the firm said the fund acquired the shares through preferred-stock conversions tied to Aspen’s IPO and a purchase of 1 million IPO shares at $15 each. OrbiMed said it made the investment for financial purposes, not to take control of Aspen.
Investor Intent
OrbiMed Advisors said it bought the shares as an investment, not to control Aspen Neuroscience. It reported no current proposals for a merger, asset sale, board or management change, or other major corporate change.
Investor's Background
OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser under the Investment Advisers Act. It serves as managing member of OrbiMed Capital GP VII LLC, which is general partner of OPI VII, the limited partnership that holds the Aspen shares. Through those roles, OrbiMed Advisors shares authority to vote and dispose of the fund’s holdings.
Original SEC Filing: Aspen Neuroscience, Inc. [ ASPE ] - SCHEDULE 13D - Nov. 06, 2026
